Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells.
作者信息
Ganapathi R, Yen A, Grabowski D, Schmidt H, Turinic R, Valenzuela R
出版信息
Br J Cancer. 1986 Apr;53(4):561-6. doi: 10.1038/bjc.1986.88.
Abstract
摘要
相似文献
1
Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells.
Br J Cancer. 1986 Apr;53(4):561-6. doi: 10.1038/bjc.1986.88.
2
3
Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxic activity of doxorubicin (adriamycin) in resistant P388 mouse leukemia cells.
Eur J Cancer Clin Oncol. 1984 Jun;20(6):799-806. doi: 10.1016/0277-5379(84)90219-0.
4
Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Biochem Biophys Res Commun. 1985 Sep 16;131(2):912-9. doi: 10.1016/0006-291x(85)91326-9.
5
Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
Biochem Pharmacol. 1986 Feb 15;35(4):673-8. doi: 10.1016/0006-2952(86)90366-7.
6
7
Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.
Cancer Res. 1983 Aug;43(8):3696-9.
8
Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
Cancer Res. 1990 Feb 15;50(4):1165-9.
9
引用本文的文献
1
Pharmacologic circumvention of multidrug resistance.
Cytotechnology. 1993;12(1-3):171-212. doi: 10.1007/BF00744664.
2
Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.
Br J Cancer. 1988 Sep;58(3):335-40. doi: 10.1038/bjc.1988.214.
3
N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
Br J Cancer. 1989 Dec;60(6):819-26. doi: 10.1038/bjc.1989.373.
4
Inhibition of vincristine binding to plasma membrane vesicles from daunorubicin-resistant Ehrlich ascites cells by multidrug resistance modulators.
Br J Cancer. 1989 Dec;60(6):809-14. doi: 10.1038/bjc.1989.371.
5
Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein.
Br J Cancer. 1989 Jan;59(1):42-6. doi: 10.1038/bjc.1989.9.
本文引用的文献
1
Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor.
Cancer Res. 1980 Apr;40(4):1077-83.
2
Membrane alterations associated with progressive adriamycin resistance.
Biochem Pharmacol. 1982 Aug 15;31(16):2691-3. doi: 10.1016/0006-2952(82)90723-7.
3
4
Calmodulin and the cell cycle: involvement in regulation of cell-cycle progression.
Cell. 1982 Jan;28(1):41-50. doi: 10.1016/0092-8674(82)90373-7.
5
T-cell control of B-cell proliferation uncoupled from differentiation.
Cell Immunol. 1982 Dec;74(2):269-76. doi: 10.1016/0008-8749(82)90027-2.
6
Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.
Cancer Res. 1983 Aug;43(8):3696-9.
7
Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxic activity of doxorubicin (adriamycin) in resistant P388 mouse leukemia cells.
Eur J Cancer Clin Oncol. 1984 Jun;20(6):799-806. doi: 10.1016/0277-5379(84)90219-0.
8
Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein.
Cancer Res. 1983 Sep;43(9):4413-9.
9
Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin.
Cancer Res. 1972 Jun;32(6):1195-200.
10
Comparison of the cellular pharmacology of doxorubicin in resistant and sensitive models of pancreatic cancer.
Cancer Chemother Pharmacol. 1985;14(2):132-4. doi: 10.1007/BF00434351.
Zotero 插件